AVITA Medical’s RECELL® GO Receives CE Mark, Expanding Access in Europe
Summary: AVITA Medical announced that its point-of-care kit, **RECELL GO**, has secured the CE Mark under EU MDR, permitting commercialization across Europe. This device enables clinicians to prepare a suspension of a patient’s own skin cells—*Spray-On Skin™ Cells*—from a small healthy skin sample, to treat burns, trauma, and surgical wounds. Early clinical data suggest this approach can reduce hospital stay significantly.
Key Highlights:
- RECELL GO builds on the established RECELL System, now optimized for more immediate or portable use across European clinical settings.
- Presentation at the 2025 European Burns Association showed ~36% reduction in hospital stay for patients with deep partial-thickness burns versus traditional grafting techniques.
- Commercial rollout planned in select European countries including Germany, Italy, and the United Kingdom; aimed at burn centers and surgical/trauma clinics.
- Skin cells harvested are autologous, avoiding donor site morbidity; supports burn repair, traumatic or surgical wound healing; likely improves cosmesis and recovery time.
Keywords:
RECELL GO,
autologous skin cells,
burn wound care,
hospital stay reduction,
AVITA Medical